Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 16/20 | 0.66 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.58 |
| ▸ | EDNRA | P25101 | 1/20 | 0.57 |
| ▸ | BACE1 | P56817 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30786597 | 0.94 | ECE1 (0.59) | KISS1RERAP2EDNRA | |
| SCHEMBL29804818 | 0.92 | KISS1R (0.63) | KISS1RERAP2BACE1 | |
| SCHEMBL30001263 | 0.92 | KISS1R (0.61) | KISS1RERAP2 | |
| SCHEMBL31388720 | 0.91 | ERAP2 (0.64) | KISS1RERAP2EDNRABACE1 | |
| SCHEMBL30786598 | 0.91 | KISS1R (0.57) | KISS1RERAP2 | |
| SCHEMBL31003039 | 0.90 | KISS1R (0.61) | KISS1RERAP2EDNRABACE1 | |
| SCHEMBL30417563 | 0.89 | ERAP2 (0.66) | KISS1RERAP2EDNRA | |
| SCHEMBL30254765 | 0.89 | ERAP2 (0.63) | ERAP2EDNRA | |
| SCHEMBL30051680 | 0.89 | ECE1 (0.66) | ERAP2 | |
| SCHEMBL31606469 | 0.88 | ERAP2 (0.64) | KISS1RERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126921-A2 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | claimed |
| CN-115335395-A | QD administration of GIP receptor agonist peptide compounds and uses thereof | 武田药品工业株式会社 | 2022-11-11 | — | — | CN | claimed |
| US-20220227830-A1 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-07-21 | — | — | US | claimed |
| EP-4126921-A2 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
| CN-115335395-A | QD administration of GIP receptor agonist peptide compounds and uses thereof | 武田药品工业株式会社 | 2022-11-11 | — | — | CN | disclosed |
| US-20220227830-A1 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227830-A1 | QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, GRPR | KISS1R 95/4885ERAP2 661/4885EDNRA 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.